Dermatológia pre prax 1/2016
Interleukin (IL)-17 – new target in psoriasis therapy
Targets for psoriasis treatment have evolved in accordance with our evolving understanding of disease pathogenesis. IL-17 is a cytokine which elicits protection against extracellular bacterial and fungal infections. Laboratory and clinical data have demonstrated that IL-17 is a key cytokine driving inflammatory pathways inherent in psoriasis pathogenesis. Therefore, IL-17 is an attractive new therapeutic target.
Keywords: IL-17, pathogenesis, psoriasis, therapy
